FindTrial
Sign In

RSVpreF

BIOLOGICAL7 trials

Sponsors

Pfizer, Hvivo

Conditions

HealthyHealthy ParticipantsLower Respiratory Tract IllnessRESPIRATORY SYNCYTIAL VIRUS (RSV)RSV InfectionRespiratory Syncytial Virus InfectionsRespiratory Tract Infection

Phase 1

A Study to Examine Respiratory Combination Vaccines Against Respiratory Syncytial Virus (RSV) and Flu in Older Adults
CompletedNCT05788237
PfizerHealthy
Start: 2023-03-09End: 2023-09-27Updated: 2024-11-22

Phase 2

Study of RSVpreF Vaccination and RSV Challenge in Healthy Adults
CompletedNCT04785612
HvivoRespiratory Syncytial Virus Infections
Start: 2020-11-10End: 2021-08-16Updated: 2024-08-07
A Study to Learn About Two or More Vaccines That Are Put Together as One Shot Against Infectious Lung Illnesses, Including COVID-19 and Respiratory Syncytial Virus (RSV).
CompletedNCT05886777
PfizerHealthy Participants
Start: 2023-06-05End: 2024-01-01Updated: 2024-12-18

Phase 3

A Trial to Evaluate the Efficacy and Safety of RSVpreF in Infants Born to Women Vaccinated During Pregnancy.
CompletedNCT04424316
PfizerRespiratory Tract Infection
Start: 2020-06-17End: 2023-10-27Updated: 2025-02-11
Study to Evaluate the Efficacy, Immunogenicity, and Safety of RSVpreF in Adults.
Active, not recruitingNCT05035212
PfizerLower Respiratory Tract Illness
Start: 2021-08-31End: 2027-01-18Updated: 2026-01-28
A Study to Assess the Safety, Tolerability, and Immunogenicity of RSVpreF in Adults at High Risk of Severe RSV Disease
CompletedNCT05842967
PfizerRESPIRATORY SYNCYTIAL VIRUS (RSV)
Start: 2023-05-11End: 2024-03-18Updated: 2025-08-08
A Phase 3 Study of Revaccination in Subsequent Pregnancies With Bivalent RSV Vaccine and Duration of Protection of a Single Dose
RecruitingNCT06866405
PfizerRSV Infection
Start: 2025-04-16End: 2028-02-24Target: 550Updated: 2026-03-18

Related Papers

Integrated Analysis of the Safety Experience in Adults with the Bivalent Respiratory Syncytial Virus Prefusion F Vaccine
Vaccines2025-08-011 citations
Immunogenicity and Safety of the Bivalent Respiratory Syncytial Virus Prefusion F Subunit Vaccine in Immunocompromised or Renally Impaired Adults
Vaccines2025-03-196 citations
Efficacy, Immunogenicity, and Safety of the Bivalent Respiratory Syncytial Virus (RSV) Prefusion F Vaccine in Older Adults Over 2 RSV Seasons
Clinical Infectious Diseases2025-02-1027 citations
Safety and Immunogenicity of Concomitant Administration and Combined Administration of Bivalent BNT162b2 COVID-19 Vaccine and Bivalent RSVpreF Respiratory Syncytial Virus Vaccine with or Without Quadrivalent Influenza Vaccine in Adults ≥ 65 Years of Age
Vaccines2025-02-053 citations
P-596. Immunobridging Demonstrating Effectiveness of the Bivalent Respiratory Syncytial Virus (RSV) Prefusion F Subunit Vaccine in Adults 18-59 Years of Age at High Risk of Severe RSV Disease in a Phase 3 Trial: The C3671023 MONeT Study Results
Open Forum Infectious Diseases2025-01-292 citations
P-605. Bivalent RSV Prefusion F-Based Subunit Vaccine Generates High and Durable Neutralizing Titers Across an Entire RSV Season among Older Adults
Open Forum Infectious Diseases2025-01-291 citations
P-600. Efficacy of a Bivalent RSVpreF Vaccine in Older Adults Across a Second RSV Season
Open Forum Infectious Diseases2025-01-29
571. Safety and Immunogenicity of Coadministered Bivalent BNT162b2 COVID-19 Vaccine and Bivalent RSVpreF Respiratory Syncytial Virus Vaccine With and Without Quadrivalent Influenza Vaccine in Adults ≥ 65 Years of Age
Open Forum Infectious Diseases2025-01-29
P-595. Public Health Impact of RSVpreF Vaccination on Older Adult Disease Outcomes
Open Forum Infectious Diseases2025-01-29
Efficacy, Safety, and Immunogenicity of the MATISSE (Maternal Immunization Study for Safety and Efficacy) Maternal Respiratory Syncytial Virus Prefusion F Protein Vaccine Trial
Obstetrics and Gynecology2025-01-0255 citations
Preterm Birth Frequency and Associated Outcomes From the MATISSE (Maternal Immunization Study for Safety and Efficacy) Maternal Trial of the Bivalent Respiratory Syncytial Virus Prefusion F Protein Vaccine
Obstetrics and Gynecology2025-01-0222 citations
Bivalent RSVpreF Vaccine in Adults 18 to <60 Years Old With High-Risk Conditions
Clinical Infectious Diseases2024-11-0713 citations
Efficacy and safety of bivalent RSVpreF maternal vaccination to prevent RSV illness in Japanese infants: Subset analysis from the pivotal randomized phase 3 MATISSE trial
Vaccine2024-06-1116 citations
1632. Bivalent RSV Prefusion F-Based Subunit Vaccine Generates High Neutralizing Titers in Older Adults
Open Forum Infectious Diseases2023-11-271 citations
1630. Clinical Profile of Acute Respiratory Illness (ARI) Events in the Phase 3 Trial The RSV Vaccine Efficacy Study iN Older Adults Immunized against RSV Disease (RENOIR)
Open Forum Infectious Diseases2023-11-271 citations
1634. Respiratory Syncytial Virus-Associated Health Care Utilization in the Pivotal Phase 3 Trial RSV Vaccine Efficacy Study In Older Adults Immunized Against RSV Disease (RENOIR)
Open Forum Infectious Diseases2023-11-27
Evaluation of Clinical Case Definitions for Respiratory Syncytial Virus Lower Respiratory Tract Infection in Young Children
Journal of the Pediatric Infectious Diseases Society2023-05-0114 citations
Bivalent Prefusion F Vaccine in Pregnancy to Prevent RSV Illness in Infants
New England Journal of Medicine2023-04-05828 citations
Efficacy and Safety of a Bivalent RSV Prefusion F Vaccine in Older Adults
New England Journal of Medicine2023-04-05566 citations
LB748. Efficacy And Safety Of Bivalent Respiratory Syncytial Virus (RSVpreF) Vaccine In Older Adults
Open Forum Infectious Diseases2022-12-013 citations

5 more papers not shown